X0306 4 2020-07-17 0 0001807901 Pandion Therapeutics, Inc. PAND 0001816744 Viney Joanne L. C/O PANDION THERAPEUTICS, INC., 134 COOLIDGE AVENUE WATERTOWN MA 02472 0 1 0 0 See Remarks Common Stock 2020-07-21 4 C 0 21133 A 503254 D Common Stock 2020-07-21 4 P 0 1200 18.00 A 1200 I By husband Stock Option (right to buy) 18.00 2020-07-17 4 A 0 56637 0.00 A 2030-07-16 Common Stock 56637 56637 D Stock Option (right to buy) 18.00 2020-07-17 4 A 0 58239 0.00 A 2030-07-16 Common Stock 58239 58239 D Series B Preferred Stock 2020-07-21 4 C 0 107768 0.00 D Common Stock 21133 0 D The Series B Preferred Stock converted into Common Stock on a 5.0994-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. Represents shares purchased through a directed share program in connection with the initial public offering of Pandion Therapeutics, Inc.'s common stock, which closed on July 21, 2020. These shares of common stock were purchased at the public offering price of $18.00 per share. This option award was granted on July 17, 2020. 1/4 of the shares underlying the award shall vest on May 21, 2021, with the remainder of the shares vesting in equal monthly installments following May 21, 2021 through May 21, 2024, subject to the reporting person's continued service on each applicable vesting date. This option award was granted on July 17, 2020. 1/4 of the shares underlying the award shall vest on June 25, 2021, with the remainder of the shares vesting in equal monthly installments following June 25, 2021 through June 25, 2024, subject to the reporting person's continued service on each applicable vesting date. President and Chief Scientific Officer /s/ Edward Freedman, as attorney-in-fact for Joanne Viney 2020-07-21